MiMedx announced that its Board of Directors has appointed Joseph Capper as the Company’s Chief Executive Officer, CEO, and a director of the Company, effective immediately. Todd Newton, who has served as the Company’s interim CEO since September 2022 will remain in his role on the Board of Directors. Capper joins MIMEDX with nearly 30 years of MedTech and Life Sciences experience. He has successfully led several organizations, most recently serving as the CEO of BioTelemetry. As a result of today’s announcement, the Board has been increased in size to nine members.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MDXG:
- MiMedx reaffirms Q4 revenue view $73M-$76M, consensus $74.53M
- MIMEDX Confirms Fourth Quarter and Full Year 2022 Net Sales Expectations, Comments on Evolving Medicare Reimbursement Landscape and Provides Corporate Updates
- MiMedx named a top pick 2023 at Northland
- MiMedx in pact with Gunze for sales of EPIFIX in Japan
- MIMEDX Announces Commercial Launch of EPIFIX® in Japan with Exclusive Distribution Agreement with GUNZE MEDICAL LIMITED
